Drug Approval | August 28, 2022
Cipla receives 6 observations from USFDA for Goa facility
There are no data integrity (DI) observations.
There are no data integrity (DI) observations.
With the receipt of the EIR, the inspection stands successfully closed.
The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.
Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of US $282 million in the US
The company continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest
Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Naproxen Sodium Capsules, 220 mg, of Bionpharma
Subscribe To Our Newsletter & Stay Updated
